NCT04604483

Brief Summary

Chronic anal fissure rarely heals spontaneously. About 50% heal on administration om topical muscle relaxants (e.g. diltiazem) and/or injection of Botulinum toxin, but for the remainder of patients surgery (with lateral internal sphincterotomy or fissurectomy) with subsequent risks of anal incontinence has been the golden standard. Treatment with PTNS (percutaneous tibial nerve stimulation) has been showed to produce healing of chronic anal fissures not responding to topical treatment, thus avoiding the risk for debilitating anal incontinence.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for not_applicable

Timeline
7mo left

Started Oct 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Oct 2024Dec 2026

First Submitted

Initial submission to the registry

October 14, 2020

Completed
13 days until next milestone

First Posted

Study publicly available on registry

October 27, 2020

Completed
3.9 years until next milestone

Study Start

First participant enrolled

October 1, 2024

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

March 1, 2024

Status Verified

February 1, 2024

Enrollment Period

2.2 years

First QC Date

October 14, 2020

Last Update Submit

February 29, 2024

Conditions

Keywords

Anal fissurePercutaneous Tibial Nerve StimulationPTNS

Outcome Measures

Primary Outcomes (2)

  • Healing rate

    Healing of anal fissure from assessement of clinical and/or data from patient form

    3 months after treatment

  • Healing rate

    Healing of anal fissure from assessement of clinical and/or data from patient form

    12 months after treatment

Secondary Outcomes (6)

  • Bowel movements

    3 months after treatment

  • Bowel movements

    12 months after treatment

  • Adverse effects

    3 months after treatment

  • Adverse effects

    12 months after treatment

  • Smoking

    3 months after treatment

  • +1 more secondary outcomes

Study Arms (1)

PTNS

EXPERIMENTAL

Treatment with PTNS for chronic anal fissure, treatment to be given for 30 minutes during 10 consecutive work Days.

Device: PTNS

Interventions

PTNSDEVICE

Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.

Also known as: Percutaneous Tibial Nerve Stimulation
PTNS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Verified anal fissure (Clinical assessement by experienced proctological surgeon)
  • Full conservative treatment has been given

You may not qualify if:

  • Inflammatory bowel disease
  • Fistula and/or anal abscess
  • Patients with compromised immunity
  • Pregnancy
  • Treatment with anti-coagulants (not aspirin)
  • Previous irradiation towards pelvic floor
  • Pacemaker or implanted defibrillator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Skåne University Hospital

Malmo, Sweden

Location

Related Publications (1)

  • Nelson RL, Thomas K, Morgan J, Jones A. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD003431. doi: 10.1002/14651858.CD003431.pub3.

    PMID: 22336789BACKGROUND

MeSH Terms

Conditions

Fissure in Ano

Condition Hierarchy (Ancestors)

Anus DiseasesRectal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • Louis B Johnson, PhD

    Lund University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Martin Lindsten, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Prospective non-randomized trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 14, 2020

First Posted

October 27, 2020

Study Start

October 1, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

March 1, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

No intention to make individual participant data available to other researchers

Locations